Das Robert-Bosch-Krankenhaus auf dem Burgholzhof in Stuttgart ist ein Stiftungskrankenhaus, das auf eine private Initiative Robert Boschs aus dem Jahr 1915 zurückgeht.

During the past decade, Robert-Bosch-Krankenhaus conducted 63 clinical trials. In the 10-year time frame, 63 clinical trials started and 20 clinical trials were completed, i.e. on average, 31.7% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 12 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Robert-Bosch-Krankenhaus" #1 sponsor was "Goethe University" with 6 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Aesculap AG" with 4 trials sponsored, "Celgene" with 4 trials sponsored and "German CLL Study Group" with 4 trials sponsored. Other sponsors include 87 different institutions and companies that sponsored additional 73 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Robert-Bosch-Krankenhaus" #1 collaborator was "B.Braun Surgical SA" with 4 trials as a collaborator, "Bayer" with 3 trials as a collaborator, "AbbVie" with 2 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 2 trials as a collaborator and "Cancer Trials Ireland" with 2 trials as a collaborator. Other collaborators include 96 different institutions and companies that were collaborators in the rest 94 trials.

According to Clinical.Site data, the most researched conditions in "Robert-Bosch-Krankenhaus" are "Acute Myeloid Leukemia" (6 trials), "Coronary Artery Disease" (6 trials), "Aortic Valve Stenosis" (5 trials), "Leukemia" (5 trials) and "Chronic Heart Failure" (3 trials). Many other conditions were trialed in "Robert-Bosch-Krankenhaus" in a lesser frequency.

Most popular intervention types in "Robert-Bosch-Krankenhaus" are "Drug" (73 trials), "Other" (18 trials), "Device" (16 trials), "Procedure" (15 trials) and "Biological" (13 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Carboplatin" (4 trials), "cyclophosphamide" (4 trials), "radiation therapy" (4 trials) and "Azacitidine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Robert-Bosch-Krankenhaus" are 110 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Robert-Bosch-Krankenhaus". undefined are not yet recruiting, 20 are recruiting, 19 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 54 completed trials in Robert-Bosch-Krankenhaus, undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Robert-Bosch-Krankenhaus, 3 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 46 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 17 trials that are defined as “Not Applicable".

Robert-Bosch-Krankenhaus has several departments that took part in Clinical trials: "Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie" - 6 trials, "Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin" - 5 trials, "Robert-Bosch-Krankenhaus, Zentrum für Innere Medizin" - 2 trials